Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium-68 Citrate PET for MYC Amplification in mCRPC
NCT02391025Phase 1Completed
- Sponsor
- Rahul Aggarwal
- Start
- May 2015
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium-68 citrate in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Rahul Aggarwal. Primary endpoints: Mean maximum Standardized Uptake Value at Day 1 and Mean maximum Standardized Uptake Value (averaged) at Day 1. Started May 2015; status: completed.
02
Drugs
gallium-68 citrate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02391025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391025.